



**SDI Review Form 1.6**

|                          |                                                                                                                               |
|--------------------------|-------------------------------------------------------------------------------------------------------------------------------|
| Journal Name:            | <a href="#">Journal of Cancer and Tumor International</a>                                                                     |
| Manuscript Number:       | 2015_JCTI_18131                                                                                                               |
| Title of the Manuscript: | <b>MiRNA and target oncogenes in Triple negative breast cancer; major players in age and ethnic related neoplastic events</b> |
| Type of the Article      | <b>Review Article</b>                                                                                                         |

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

|                                            | <b>Reviewer's comment</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b><u>Compulsory</u></b> REVISION comments |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                                                                                                                                                                      |
| <b><u>Minor</u></b> REVISION comments      | <p>1/ Do the results up to now support a definite framework for clinical development of microRNAs inhibitors-based therapeutic strategy in this still incurable disease?</p> <p>2/ Do familial cases prevent us from observing a direct effect of microRNAs (for example miR-342 on BRCA1)?</p> <p>3/ Please have a look to the following link. It appears to include very helpful information enabling authors to improve their discussion and conclusions:<br/> <a href="http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087039">http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087039</a></p> |                                                                                                                                                                                      |
| <b><u>Optional/General</u></b> comments    | Excellent review covering extensively this particular field of research. Authors are advised to include a few sentences in discussion and in conclusions as far as future therapeutic strategies are concerned in relation to miRNAs                                                                                                                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                      |

**Reviewer Details:**

|                                  |                                                         |
|----------------------------------|---------------------------------------------------------|
| Name:                            | <b>Evangelos Marinos</b>                                |
| Department, University & Country | <b>School of Medicine, University of Athens, Greece</b> |